Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has
become an important and accepted therapeutic treatment for malignant
disorders. Hematopoietic stem cells can be obtained from bone marrow
through multiple aspirations or alternatively from peripheral blood
after stimulation with granulocyte colony-stimulating factor (G-CSF).
G-CSF has been indicated to promote
the mobilization and differentiation of hematopoietic stem cells and is
now a widely used scheme in HSCT [1]. However, the
mobilization efficiency of G-CSF varies individually; that is, poor
mobilization occurs in 25% of patients with hematological malignancies
and in 10%-20% of healthy donors [2].
G-CSR is a highly specific receptor that binds G-CSF and induces a
series of signaling cascades, leading to different biological events[3,4]. Genomic sequencing of the CSF3R locus has
identified many intronic polymorphisms and four synonymous coding
mutations [5], therefore discrepancies in the
CSF3R gene, whether caused by SNPs or mutations, that have been proven
to be associated with an abnormal response to G-CSF treatment[6,7,8]. However, most current studies focus on
the effect of CSF3R polymorphisms on the occurrence or progression of
disease in patients [9]. Donor-derived
hematopoietic stem cells are the products responding to G-CSF treatment.
Bahar et al used PCR-RFLP technology to study whether differences in
CSF3R SNP loci of healthy donors and hematological tumor patients would
affect the enrichment of peripheral blood CD34+ cells,
and the results showed that different SNP loci have different
mobilization efficiencies for different individuals. Among them, healthy
donors carrying the rs3918018 A/A genotype had significantly less
efficient CD34 + collections in the first two attempts
than donors carrying the G/G genotype [10]. Since
the number of CD34 molecules is related to cell implantation,
reconstruction and other events post allo-HSCT and CSF3R polymorphism
may directly affect the prognosis of transplantation, whether the
clinical prognosis of patients after HSCT will be affected by donor
CSF3R polymorphisms has not yet been elucidated. Thus, the aim of the
study was to screen CSF3R SNPs and therefore explore whether donor CSF3R
SNPs can affect the clinical outcomes of patients post allo-HSCT.